Compare BARK & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BARK | KRRO |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.7M | 109.7M |
| IPO Year | N/A | 2019 |
| Metric | BARK | KRRO |
|---|---|---|
| Price | $0.63 | $10.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $2.50 | ★ $34.80 |
| AVG Volume (30 Days) | ★ 893.9K | 204.9K |
| Earning Date | 02-05-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,392,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.43 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 181.46 |
| 52 Week Low | $0.53 | $5.20 |
| 52 Week High | $1.48 | $55.89 |
| Indicator | BARK | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 28.04 | 43.23 |
| Support Level | $0.53 | $10.55 |
| Resistance Level | $0.86 | $14.96 |
| Average True Range (ATR) | 0.05 | 0.87 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 8.88 | 2.55 |
BARK Inc is a vertically integrated, omnichannel brand serving dogs across two key categories: toys & accessories and consumables. It serves dogs nationwide with monthly subscription services, BarkBox and Super Chewer; e-commerce experience on BarkShop.com; custom collections via its retail partner network, including Target and Amazon; wellness products that meet dogs' needs with BARK Bright; and a personalized meal delivery service for dogs BARK Eats. The company's reportable segments are; Direct to Consumer (D2C), and Commerce. The majority of its revenue is generated from the Direct to Consumer segment which derives revenue from the sale of toys & accessories and consumables through BarkBox, Super Chewer, and the company's consumables website.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.